Trial Profile

Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG12D-Mutant Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zoldonrasib (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer; Pancreatic ductal carcinoma; Solid tumours
Focus Adverse reactions
Sponsors REVOLUTION Medicines

28 Aug 2025 Planned number of patients changed from 444 to 604.
30 Apr 2025 Results assessing the preliminary safety and antitumor activity of zoldonrasib RMC-9805 in patients with KRAS G12D non-small cell lung cancer from a phase 1 study in advanced solid tumors were published at the 116th Annual Meeting of the American Association for Cancer Research.
27 Apr 2025 According to a Revolution Medicines media release, Kathryn Arbour, M.D., thoracic medical oncologist at Memorial Sloan Kettering Cancer Center is the principal investigator of this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com